In 2023, the worldwide stopcock market achieved a total valuation of $175.1 million, reflecting a 5.7% increase compared to the $165.7 million recorded in 2022. Projections for the upcoming period suggest a sustained growth trajectory, with a compound annual growth rate (CAGR) of 4.9%, ultimately reaching $245.5 million. Presently, the global stopcock market is under the dominance of Becton Dickinson (BD) and B. Braun.
Our comprehensive medical market research involved a thorough analysis of more than 20 stopcock companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
During the same year, B. Braun secured its position as the second most influential competitor in the global stopcock arena. Renowned for its expertise in infusion pump manufacturing, B. Braun adopts a distinctive approach by bundling its stopcock devices with other medical equipment. Many hospitals prefer a comprehensive sourcing approach, choosing to procure the majority of their infusion products from a single manufacturer. This strategic advantage significantly enhances B. Braun's standing in the stopcock market, particularly in Western Europe, where it consistently excels across a diverse range of medical devices.
The lower tiers of the global stopcock market landscape are predominantly occupied by smaller, localized competitors. These agile players specialize in producing straightforward, cost-effective products tailored for hospital use. Nevertheless, their market share remains modest compared to industry giants capable of bundling stopcock sales with a comprehensive suite of infusion therapy products. Notably, companies like B. Braun and Becton Dickinson, among others, reign supreme in this category, leveraging their extensive product portfolios to maintain a dominant presence.
Our comprehensive medical market research involved a thorough analysis of more than 20 stopcock companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2030, and Historical Data to 2020
- Market Drivers & Limiters for Each Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
COVID-19 Impact
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
GLOBAL STOPCOCK MARKET INSIGHTS
Stopcocks are encountering competition from emerging needleless connectors, which are gaining recognition as alternative technologies in the market. Needleless connectors offer various advantages, such as improved infection control, reduced fluid wastage, and enhanced precision in fluid management. These connectors are increasingly becoming more accessible and adopted, influencing traditional segments of the stopcock market. As needleless connectors continue to gain popularity, they are gradually displacing conventional stopcocks in specific applications and healthcare settings.GLOBAL STOPCOCK MARKET SHARE INSIGHTS
In 2023, Becton Dickinson (BD) emerged as the undisputed leader in the global stopcock market, solidifying its dominant position in the industry. BD proudly offers two significant offerings: the Alaris® lipid-resistant, 3-way stopcock, and an alternative latex- and PVC-free version of this essential medical device. BD's commanding influence extends not only to North America and Western Europe, where it holds the second-largest market share, but also to numerous regional markets across the globe.During the same year, B. Braun secured its position as the second most influential competitor in the global stopcock arena. Renowned for its expertise in infusion pump manufacturing, B. Braun adopts a distinctive approach by bundling its stopcock devices with other medical equipment. Many hospitals prefer a comprehensive sourcing approach, choosing to procure the majority of their infusion products from a single manufacturer. This strategic advantage significantly enhances B. Braun's standing in the stopcock market, particularly in Western Europe, where it consistently excels across a diverse range of medical devices.
The lower tiers of the global stopcock market landscape are predominantly occupied by smaller, localized competitors. These agile players specialize in producing straightforward, cost-effective products tailored for hospital use. Nevertheless, their market share remains modest compared to industry giants capable of bundling stopcock sales with a comprehensive suite of infusion therapy products. Notably, companies like B. Braun and Becton Dickinson, among others, reign supreme in this category, leveraging their extensive product portfolios to maintain a dominant presence.
MARKET SEGMENTATION SUMMARY
- Stopcock Market
Table of Contents
- Executive Summary
- Global Stopcock Market Overview
- Competitive Analysis
- Regions Included
- Introduction
- Market Analysis and Forecast
- Drivers and Limiters
- Market Drivers
- Market Limiters
- Competitive Market Share Analysis
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton Dickinson
- B. Braun
- ICU Medical
- Vygon
- Cair
- Terumo
- CODAN
- Baxter
- Didactic
- Rays
- Benefis
